

Cannasouth Limited

Fact Sheet 2023



Cannasouth Highlights

- Vertically integrated biopharmaceutical company. Activities include advanced research, cultivation, product development, internal testing capability, manufacture, sales, and online prescribing clinic (seed to sale).
- New Zealand's first medicinal cannabis company to list on the New Zealand Stock Exchange (NZX:CBD) in June 2019, with circa 28,000 shareholders including via custodian.
- Developed next-generation Controlled Environment Agriculture (CEA) sealed greenhouse and post-harvest facility. The facility allows year-round cultivation of premium GACP/GMP compliant cannabis flower at industry-leading production costs and with a lower environmental impact than indoor operations.
- End-to-end EU GMP manufacturing for cannabis dried flower, active ingredients and oral solutions.
- Premium product range, encompassing dried flower, oral solutions, topicals and bulk ingredients.
- Connect patients with doctors via our own telehealth clinic, RestoreMe.
- Proprietary IP which includes low-cost production, next generation drug delivery, topical and individualised medicine system.
- Pure New Zealand provenance, grown in the Waikato & Bay of Plenty regions, the agricultural and horticultural heartland of New Zealand.

Key Milestones

First medicinal cannabis company to list on NZX Main Board in June 2019

Purchased a 60% stake in Midwest Pharmaceuticals NZ Ltd

Submitted product assessment applications to the Medicinal Cannabis Agency in November 2020 for three imported Cannabisown branded medicines

Purchased remaining 50% stake of Cannasouth Cultivation Ltd. This completes the Cannasouth group consolidation, with all subsidiary companies now 100% owned by Cannasouth Ltd (NZX:CBD)

First commercial harvest in CEA cultivation facility

Achieved GACP certification at cultivation facility

Sold non-core assets of Midwest Pharmaceuticals NZ Ltd

Merged with Equalis Group New Zealand Ltd

Registration of new dried flower and oral solution products for launch in New Zealand

Commercialisation of first products from R&D pipeline

2019	2020	2021	2022	2023	NEXT STEPS
Established a joint venture, Cannasouth Cultivation Ltd, to grow and process cannabis	Cannasouth Cultivation Ltd appointed noted Colorado cultivator, Vera Cultivation, to support the commissioning and operations for the new facility.	Purchased remaining 40% stake of Midwest Pharmaceuticals NZ Ltd	Commissioned a state-of-the-art cultivation and post-processing facility.	Signed a supplier agreement with WEECO Pharma GMBH, one of the leading importers and distributor of medicinal cannabis in Germany	Sales of first Cannasouth branded cannabis medicines in New Zealand
				GMP certification of cultivation facility	First exports of premium cannabis flower and CBD cannabis-based ingredient to Australia
					Expand range of APIs and finished products to include THC containing cannabis-based ingredients and products, including in oral and topical forms

Cannasouth Licences

Cannasouth holds commercial Medicinal Cannabis Licences to operate across **six sites**, encompassing activities of;


- Cultivation,
- Possess for manufacture and supply, and
- Manufacturing medicines (to the globally recognised GMP standard).

We have products verified by the Medicinal Cannabis Agency that meet the New Zealand Minimum Quality Standard, with further product applications in process.

Facilities and Locations

Head office and laboratory	📍 Hamilton
GMP flower production	📍 Morrinsville
GMP pharmaceuticals production	📍 Katikati
Pharmaceuticals and cultivation innovation	📍 Katikati
Outdoor cultivation	📍 Matakana Island
Outdoor cultivation	📍 Timaru
RestoreMe Clinic	📍 Katikati / cloud

Innovation



Successful post-graduate studies in collaboration with the University of Waikato and Callaghan Innovation have provided valuable information related to:

- Plant cultivation
- Extraction of bioactive compounds
- The clinical potential for cannabinoids in neuropathic pain.

Callaghan grants have also allowed Cannasouth to develop novel drug delivery technologies that will lead to the next generation of therapeutic products.

This research combined with our pre-clinical studies allows Cannasouth to search for genuine unique IP opportunities, develop clinical trial strategies, and develop innovative new products and formulations for both the local and export markets.

Our Innovation Team has successfully developed 'in-house' analytical testing services (biological and chemical) and a genetics onboarding capability to support our commercial cultivation business.


The company also has a suite of innovative products and technologies covering cultivation and extraction designed to reduce costs of production and deliver future shareholder returns.

Share Information

As at 1 October 2023

NZX Main Board Code:	CBD
Share Price:	\$0.22
Shares on issue:	320,533,594
Market capitalisation:	\$70,517,690
Financial year-end:	31 December

Company Structure



Governance



Tony Ho
Independent Non-Executive
Chairman



Christine Pears
Independent Non-Executive
Director



Mark Lucas
Executive Director and
Chief Executive Officer



Mark Scapens
Non-Executive Chairman



Hilary Webber
Independent Non-Executive
Director



Greg Misson
Managing Director and
Chief Innovation Officer

Executive

For biographies, refer to the website <https://www.cannasouth.co.nz/about/our-team/>



Mark Lucas
Chief Executive Officer
and Managing Director



Colin Foster
Chief Financial Officer
and Company Secretary



Tony Clark
Chief of Manufacturing



Pierre Booysen
Chief of Compliance



Greg Misson
Chief of Innovation



David Macaskill
Chief Commercial Officer



Brendon Ogilvy
Chief Executive Officer -
RestoreMe

Company Information:

Cannasouth Limited
Level 2, CRV Building
Waikato Innovation Park
2 Melody Lane
Hamilton East
Hamilton 3216
Phone: +64 7 949 8393
Email: enquiries@cannasouth.co.nz

Investor Enquiries:

Niki Mills
Head of Shared Service Department (Investor Relations Officer)
Phone: +64 7 949 8393
Email: enquiries@cannasouth.co.nz

For Shareholder Support Services:

Link Market Services Limited
Email: enquiries@linkmarketservices.com
Phone: +64 9 375 5998
Fax: +64 9 375 5990

LEARN MORE AT
CANNASOUTH.CO.NZ

enquiries@cannasouth.co.nz
+64 (0)7 949 8393

[!\[\]\(17413706fd4997a1a4bdf85c6864eee1_img.jpg\)](#) [!\[\]\(f419710cbe076aa30a9c6c031b5cbe84_img.jpg\)](#) [!\[\]\(2726020a4107bdc9042b257034f90eb3_img.jpg\)](#) @cannasouth

Level 2, CRV Building,
Waikato Innovation Park,
2 Melody Lane, Hamilton East,
Hamilton 3216, New Zealand

PO Box 28132,
Rototuna,
Hamilton 3256,
New Zealand

